Carbetocin versus oxytocin for the prevention of uterine atony during cesarean delivery: a real-world retrospective historical control cohort study (2022–2023)
Main findingResult — go to the resultOdds ratio 0.53 95% CI 0.41–0.68Authors' conclusion
In this single-center retrospective cohort, carbetocin was associated with reduced administration of additional uterotonics, a lower decrease in postoperative hemoglobin, and reduced transfusion compared with an oxytocin regimen of single bolus plus infusion during cesarean delivery.
Study context
- Population
- Consecutive women undergoing cesarean delivery at a single academic center
- Participants
- 1,349 women
- Exposure
- Oxytocin vs Carbetocin
- Oxytocinn = 659reference
- Carbetocinn = 690
- Outcome
- Need for additional uterotonics
Methodological detailsbefore-and-after, historical control, single-centre
- Before-and-after
- Historical control
- Single-centre
Main finding
As reported in the abstract
Odds ratio
0.53
95% CI 0.41–0.68
P < 0.001
Events by group
Carbetocin vs Oxytocin
OR 0.53 (95% CI 0.41–0.68); P < 0.001
Observational data: associations, not effects.
Secondary outcomes
RBC transfusion
P = 0.030
Median, g/dL
| Outcome | Oxytocin | Carbetocin | Difference (g/dL) | P value |
|---|---|---|---|---|
| Postoperative Hb decrease (within 24 ± 6 h)Uncertain clinical significance | 1.2 (IQR 0.6–2.0) | 1.0 (IQR 0.4–1.6) | 0.2 | P < 0.001 |
Original publication
Carbetocin versus oxytocin for the prevention of uterine atony during cesarean delivery: a real-world retrospective historical control cohort study (2022–2023). Int J Obstet Anesth. Published 6 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →